Peter McCullough, MD, MPH
Type of study:
This study compares the safety and efficacy of the drug MK-1242 (Vericiguat) compared with placebo added to the best usual treatment of patients diagnosed with heart failure with reduced ejection fraction (HFrEF).
“Baylor Scott and White Heart and Vascular Institute is pleased to offer this study to our patients who have been recently hospitalized due to heart failure. This is in an exciting new class of medications that has favorable effects on the heart, blood vessels, and kidneys in preclinical studies. Because it is given in addition to usual medications for heart failure, particular attention is paid to blood pressure and laboratory changes. In my view, we have had tremendous success with heart failure and medications such as this hold the promise of providing improvements in symptoms and reducing the risk of hospitalization and other complications.”
Dr. Peter McCullough, MD, principal investigator
The effectiveness and safety of Vericuguat in heart failure patients with reduced ejection fraction will be studied using two groups – one group that receives Vericuguat and a control group that will receive a placebo. The hypothesis of the study is that using Vericuguat with this patient population will increase the time to first occurrence of the composite of cardiovascular death or heart failure hospitalization in study participants with reduced ejection fraction.
Main/critical inclusion and criteria:
A complete list of inclusion and exclusion criteria can be found at https://www.clinicaltrials.gov/ct2/show/study/NCT02861534?term=vericiguat&cond=Heart+Failure&rank=1#locn
Laura Clariday, Laura.Clariday@BSWHealth.org or call 214-820-7224.